Immix Biopharma (IMMX) Long-Term Debt Issuances (2021)
Immix Biopharma's (IMMX) quarterly Long-Term Debt Issuances came in at $100000.0 in Q2 2021, little changed quarter-over-quarter from $100000.0 in Q1 2021.
Immix Biopharma (IMMX) Long-Term Debt Issuances (2021) Analysis & Trends
Immix Biopharma has disclosed Long-Term Debt Issuances across 1 years of filings, most recently posting $100000.0 for Q2 2021.
- Long-Term Debt Issuances for Q2 2021 came in at $100000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2021 was $200000.0 (changed N/A YoY), and the FY2021 annual result was $200000.0, changed N/A from the prior year.
- Long-Term Debt Issuances came in at $100000.0 for Q2 2021 at Immix Biopharma, roughly flat from $100000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $100000.0 in Q1 2021 to a low of $100000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |
| Mar 31, 2021 | 100,000.00 |